We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cobra Bio-Man. | LSE:CBF | London | Ordinary Share | GB0031704835 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 2.25 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 2131W
Cobra Bio-Manufacturing PLC
09 June 2008
For Immediate Release 9th June 2008
Cobra Biomanufacturing Plc
Cobrabio Announces Manufacturing Agreement with ViroMed for VM206RY
Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has
signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast,
ovarian, pancreatic, and stomach cancers). Under the agreement, Cobrabio will produce ViroMed's Master Cell Bank and GMP-grade VM206RY for
clinical trials which will be held in Korea and in the United States.
Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
"We are delighted to continue our partnership with ViroMed. In a recent ViroMed project, Cobrabio demonstrated that our commitment to
world class science, cGMP quality compliance and customer service provides the additional resources that leading biotech companies such as
ViroMed require to drive their research and development programmes forward. ViroMed is Cobra's first client in Asia and we are pleased to
extend our services to this fast-growing life sciences market."
Dr. Sunyoung Kim, CEO of ViroMed Co., Ltd. said:
"We are pleased to extend our relationship with Cobrabio to our VM206RY plasmid project. ViroMed is a rapidly expanding company with a
growing pipeline of products in development and it is vital that we work with partners who can match our scientific expertise as well as our
commitment to quality."
- ENDS -
For further information, please contact:
Cobra Biomanufacturing Plc Tel: +44 (0) 1782 714 181
Simon Saxby, Chief Executive Officer
Buchanan Communications Tel: +44 (0) 207 466 5000
Tim Anderson/Rebecca Skye Dietrich
College Hill Life Sciences Tel: +44 (0) 20 7457 2020
Gemma Price
Seymour Pierce (NOMAD & Broker) Tel: +44 (0) 207 107 8000
Stuart Lane
Notes to Editors:
About Cobra Biomanufacturing Plc:
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992,
Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and
recombinant protein products.
Cobrabio has developed a range of unique, patented technologies, which underpin a successful revenue generating contract manufacturing
business.
www.cobrabio.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFKAKNPBKDCAK
1 Year Cobra Bio-manufacturing Chart |
1 Month Cobra Bio-manufacturing Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
